What Elase Treats: Main Uses and Benefits

The therapeutic applications of Elase Ointment may assist with managing symptoms related to localized discomfort by helping to remove physical barriers from the injury site. The removal of non-viable material may be considered important for supporting the wound healing process.

Targeted Cleansing for Tissue Repair

Elase is commonly used across conditions characterized by periods of heightened symptoms such as chronic ulcerative lesions (including pressure, venous stasis, and arteriosclerotic ulcers), second- and third-degree burns, and various postoperative sites. The medication is applied in addressing the localized burden of persistent biological debris, including thick, non-viable slough, necrotic tissue, and accumulated purulent exudate. This approach helps address symptom clusters where debris creates noticeable functional strain.

For women, it provides targeted symptomatic support in the management of specific gynecologic lesions, such as benign cervicitis and vaginitis. This general therapeutic use assists with maintaining functional stability and eases distress by helping manage the associated debris.

Quick Fact: Relief for Obstructive Material
Primary Purpose	Used for managing the accumulated non-viable material (debris) in the wound.
Benefit	Helps improve day-to-day comfort during symptomatic periods.
Context	Applied in clinical settings that involve conditions presenting with systemic or localized discomfort.

Regulatory References

1. NCBI Bookshelf StatPearls overview on Wound Debridement

Eligibility Map: Who can and cannot use Elase Ointment — Official Regulatory Information

Contraindicated Populations

The use of Elase Ointment is absolutely contraindicated for patients who have a known hypersensitivity (allergy) to its active ingredients, Fibrinolysin and Desoxyribonuclease, or to any other component of the formulation. Due to the bovine origin of the fibrinolysin enzyme, the medicine must also not be used by individuals with a documented sensitivity to materials of bovine origin.

Eligibility Scope and Restrictions

Population Group	Eligibility Status (Regulatory)
Route of Administration	Strictly limited to topical use; parenteral use (injection) is contraindicated as per regulatory documents.
Pregnancy and Lactation	Use is restricted and defined as conditional; the medicine should be used only if clearly needed.
Age (Adults)	Use is established and permitted for the adult population.
Age (Pediatric)	Use is generally considered not established or documented for children and adolescents.

Official regulatory documents define the eligibility profile through absolute exclusions based on known allergies to the components or source material. Use in vulnerable populations like pregnant or breastfeeding individuals is conditionally restricted, and eligibility for children is considered not established.

Elase Interactions with other medicines and products

The interaction profile for Elase Ointment (Fibrinolysin and Desoxyribonuclease) is officially governed by its topical, localized application, which results in minimal expected systemic exposure. Consequently, the official regulatory documentation from agencies like the U.S. Food and Drug Administration (FDA) characterizes its interaction profile as one with No Known Drug Interactions.

---

Officially Documented Interaction Patterns

Interaction Type	Official Regulatory Statement
Drug-Drug Interactions	None documented. The official label states “No known drug interactions” with other medicinal products.
Metabolic Interactions	None documented. The label does not list any interactions involving metabolic enzymes, such as the CYP450 system.
Pharmacodynamic Interactions	None documented. No additive or synergistic effects with co-administered medicines are specified.

---

Interaction Constraints and Context

The regulatory profile does not list any combinations as formally contraindicated due to interaction risk, nor does it impose mandatory timing restrictions for administration alongside other treatments. Furthermore, the labeling explicitly states there are No known alcohol/food interactions, simplifying the constraints around administration relative to meals. The documented absence of interactions means the official regulatory constraints are minimal, and no restrictions are specified regarding population-specific interaction considerations (e.g., in patients with hepatic impairment).

The mechanism of Elase is rooted in the localized, non-systemic action of its dual enzyme system, which results in specific chemical debridement by targeting the molecular structure of non-viable tissue components. The medication initiates targeted chemical reactions that degrade the structural framework of debris.

Hydrolysis of Fibrin and Extracellular DNA

This domain covers the primary molecular targets and the specific chemical reactions resulting in the liquefaction and breakdown of non-viable material. The two enzymes, Fibrinolysin and Desoxyribonuclease ( DNase), execute complementary hydrolytic actions. Fibrinolysin specifically acts as a protease to cleave Fibrin, the insoluble protein scaffolding of necrotic tissue. Simultaneously, Desoxyribonuclease acts as a nuclease to break down highly polymerized Extracellular DNA released by dead cells, which contributes to the viscous, thick consistency of pus.

Mechanistic Synergy and Viscosity Reduction

This domain explains how the two mechanisms combine to produce the observable functional effect. The synergy of the dual action results in the combined degradation of complex biological debris, which is typically a mixture of both DNA and Fibrin. The dual-pronged molecular attack reduces the physical tenacity of the debris and severely cuts the viscosity of purulent exudate. This concerted breakdown results in selective chemical debridement by ensuring the material is loosened and liquefied.

How to Use Elase

The usage of Elase Ointment, a combination product containing fibrinolysin and desoxyribonuclease, follows specific administration guidelines. These instructions specify the appropriate administration routes, required preparation steps, and dosing schedules necessary for its intended use.

---

Administration and Dosage Patterns

The medicine is approved for two primary routes of administration: topical application (on the skin) and intravaginal deposition. The dosing regimen is tied to the specific route.

Route of Administration	Standard Dosing Principle	Frequency and Duration
Topical Use	Apply a thin layer of ointment to the affected area.	Must be replenished at least once daily (may be repeated up to three times a day) for as long as enzymatic action is required.
Intravaginal Use	Deposit 5 ml of the ointment deep into the vagina.	Typically administered once nightly at bedtime for a defined course of approximately five applications.

---

Procedural Context and Preparation

Proper use of the ointment requires specific procedural conditions to maximize its application. For topical use, the area must be cleansed and gently dried before the ointment is applied. A crucial instruction is the requirement to remove any dense, dry eschar before the enzymatic debridement process is initiated, as the enzyme must be in constant contact with the non-viable substrate. Furthermore, accumulated liquefied debris must be periodically removed during the course of treatment to allow the enzyme access to underlying material. This procedural structure ensures the medicine is used in accordance with established application procedures.

Research Evidence Overview

This section summarizes the official clinical research and study designs used in the evaluation of Elase Ointment (Fibrinolysin and Desoxyribonuclease), focusing only on the types of evidence that exist for its intended use as an enzymatic debriding agent. Research in this area explores the physical removal of non-viable material rather than outcomes related to systemic disease.

Evidence for Use in Chronic Ulcers

The research exploring the use of Elase for debridement in chronic ulcers includes Randomized Controlled Trials (RCTs) and comparative studies. These studies were used in research examining the physical process of debridement in chronic wounds such as venous stasis ulcers and pressure ulcers. Studies primarily focused on short-term outcomes and defined time intervals, such as the rate at which dead tissue (necrosis and slough) was removed.

Findings describe patterns observed in the studies that monitored the physical breakdown of fibrin and DNA components, materials known to be major parts of biological debris. Research focused mainly on the acute debridement phase, and the evidence quality varies across studies, with findings sometimes being mixed, particularly in complex ulcers with underlying conditions. What remains less established are the long-term outcomes following debridement with this agent. Follow-up durations were limited, meaning data for sustained healing or recurrence rates are not well characterized.

Evidence for Use in General Infected Wounds and Burns

Research has also explored the use of the product in clinical situations beyond chronic ulcers, including general infected wounds and certain types of second- or third-degree burns where significant purulent material is present. These studies typically involved clinical observations and non-comparative trials. The research explored the use of the product on purulent material and necrotic debris from general infected wounds, surgical sites, and certain types of burns.

Study Design Context and Scope

Long-Term Follow-up and Durability of Study Findings

The clinical evaluation primarily focused on immediate function. As such, the follow-up durations were limited in most key studies. This means that long-term effects are not fully established, and there is limited information for outcomes such as the final quality of wound healing or the prevention of recurrence. The results apply primarily to the short observation periods studied.

Key Studies & References

1. Overview of Elase Ointment - GlobalRx (Indications and Pharmacological Action Summary)

Common questions about Elase (FAQ)

---

Q: Is Elase the same as other products used for the same condition?

Elase is officially classified as an enzymatic debriding agent. This means its purpose is to chemically cleanse tissue. Regulatory information indicates it contains a unique combination of two distinct active enzymes: Fibrinolysin and Desoxyribonuclease, which defines its specific pharmacological action.

---

Q: Is Elase considered a high-risk medication?

Regulatory documents indicate that Elase is a topical treatment with minimal systemic absorption. Consistent with this, the official safety profile describes adverse reactions as typically local and transient (temporary) effects at the site of application.

---

Q: What is the difference between Elase and similar-sounding branded products?

Elase is the brand name for the specific combination product that contains the two active enzymes: Fibrinolysin and Desoxyribonuclease. It is the combination of these two components that gives the product its specific properties as an enzymatic debriding agent.

---

Q: What should I do if I notice a possible side effect from Elase?

The official product information describes the guidance as informing a healthcare provider if an effect continues or becomes bothersome. This is standard guidance for ensuring appropriate oversight of the treatment.

---

Q: Can I use other topical products at the same time as Elase?

The regulatory profile for Elase characterizes the product as having no known drug interactions with other medicinal products. Because it is a localized treatment with minimal systemic absorption, official documents do not list common constraints associated with general drug interactions.

---

Q: Is it normal to feel a slight stinging or warmth when using Elase?

The official safety documentation emphasizes that local effects are generally mild and temporary. The most frequently noted effect is described as temporary redness or other mild local symptoms at the site of application.

---

Q: Are there any special considerations for people with diabetes using Elase?

The official eligibility and safety documents for Elase do not list any specific restrictions or warnings regarding its use in individuals with diabetes. Eligibility restrictions are focused on known allergies to the product's components and materials of bovine origin, as well as the mandate against parenteral use.

---

Q: How is the effectiveness of Elase generally measured in clinical trials?

Clinical trials for Elase were focused on the short-term outcomes of debridement. The effectiveness was primarily measured by assessing the rate at which non-viable materials, such as necrosis and slough, were physically removed from the treatment area over a defined period.

---

Q: Can Elase be used by elderly people?

The official eligibility documents establish and permit the use of Elase for the general adult population. There are no specific age-related restrictions or warnings documented for older adults.

---

Q: Is Elase suitable for children or adolescents?

According to official regulatory documents, the use of Elase for children and adolescents is generally considered not established or documented. The statement 'generally considered not established or documented' is used in official documents regarding use in these age groups.

---

Q: Are there any age limits for using Elase?

The official eligibility profile permits use for adults. However, official documents indicate that use for children and adolescents is not established or documented within the scope of the drug's regulatory profile.

---

Q: What if I forget to use Elase at the intended time?

Official patient information states that if a scheduled application is missed, it should be applied as soon as it is remembered. The official guidance is to resume the usual schedule. Official instructions state that extra ointment should not be used to compensate for a missed application.

---

Q: Are there any major medical conditions that make someone ineligible for Elase?

The official regulatory documents list a few key restrictions. The only absolute restriction documented is a known hypersensitivity (allergy) to the active ingredients or to any components of the ointment, including materials of bovine origin.

---

Q: What should be avoided while using Elase?

The use of Elase is strictly contraindicated for patients with a known hypersensitivity to any of its components or to materials of bovine origin. Official documents also specify that this product is for topical use only, and parenteral use (injection) is contraindicated.

---

Q: Can Elase be used during pregnancy?

Official regulatory documents define the use of Elase during pregnancy as conditional and restricted. The regulatory phrasing indicates that use is determined based on clear medical need.

---

Q: Is it safe to use Elase while breastfeeding?

Similar to pregnancy, the use of Elase while breastfeeding is restricted and defined as conditional in official documents. The regulatory phrasing indicates that use is determined based on clear medical need.

---

Q: What does it mean if the product is described as a proteolytic agent?

The term proteolytic is used to describe the action of the enzyme Fibrinolysin, which is one of the active ingredients in Elase. A proteolytic agent specifically works to chemically break down, or cleave, the structural protein known as fibrin.

---

Q: Is Elase known to cause dependence or withdrawal symptoms?

The safety profile for this topical medicine is focused on local application site effects and minimal systemic absorption. Official regulatory documents do not list any concerns regarding physical dependence or withdrawal symptoms associated with its use.

Elase Ointment (Fibrinolysin and Desoxyribonuclease) must be stored under specific environmental and temperature controls as mandated by regulatory documents to preserve the stability of the enzymatic ingredients.

Official Storage and Disposal Requirements

Item	Requirement Based on Regulatory Labeling
Temperature Requirements	Store at controlled room temperature, between 15 C and 30 C (59 F and 86 F).
Prohibited Conditions	Do not refrigerate or freeze. Avoid exposure to excessive heat or direct light.
Container Rules	Keep the container tightly closed and store the medicine in its original packaging.
Child Safety	The product must be stored out of the sight and reach of children.
Disposal Instructions	Unused or expired Elase Ointment must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of via household wastewater or trash unless instructed by local guidelines.